Clone GIR208 is most commonly used in vivo in mice as an isotype control antibody, especially in studies involving type I or type II interferon signaling. GIR208 recognizes human IFNγ receptor alpha but does not interact with mouse interferongamma receptors, making it suitable as a negative control for specificity assessments in mouse models.

Key in vivo applications in mice include:

• Isotype control: In immunological studies, particularly where other antibodies (such as antimouse IFNAR1 clone MAR15A3) are used to block cytokine signaling, GIR208 is administered to control for nonspecific effects of antibody injection.
• Functional assays: GIR208 can serve as an isotype control in functional experiments to verify that observed effects are due to specific antibodytarget interactions rather than nonspecific immune modulation.
• Negative control in infection models: GIR208 is used as a comparator in viral or infectious disease mouse models. For example, in studies of dengue virus infection, mice treated with GIR208 showed no weight loss or clinical signs, and tissues tested negative for viral RNA, confirming its role as an inert control compared to diseasemodifying antibodies.

Important context:

• Does not block mouse cytokine receptors: GIR208 specifically binds human IFNγ receptor alpha, and does not bind or block the analogous mouse receptor. This property explains its use exclusively as a negative control, rather than as a functional or therapeutic antibody in mice.
• Recommended pairings: GIR208 is often used alongside clone MAR15A3, a functional antimouse IFNAR1 antibody, allowing distinction between isotype effects and true cytokine blockade in murine systems.

Summary of typical use:

• GIR208’s primary in vivo role in mice is as a negative/isotype control to validate findings of specificity and rule out offtarget or nonspecific antibody effects within immunological and infectious disease models. It is not used therapeutically or diagnostically in mouse models because of its lack of reactivity with mouse IFNγ receptors.

Commonly used antibodies or proteins with GIR208 (antihuman CD119, IFNγ receptor alpha) in the literature include other antibodies targeting the interferongamma signaling pathway, with GIR301 and isotype controls such as MOPC21 being the most frequently mentioned companions.

Key details include:

• GIR301: This is another monoclonal antibody against a component of the IFNγ receptor complex and is often paired with GIR208 in functional studies to compare or validate results within the IFNγ signaling context.
• Isotype control antibodies: Controls such as Mouse IgG1, κ (e.g., MOPC21) are important for ensuring specificity in flow cytometry and immunoassays when using GIR208.
• Recombinant human IFNγ protein: Sometimes used in competition experiments to validate GIR208 binding specificity, since excess IFNγ can inhibit GIR208 binding to CD119.
• Other IFNγR antibodies: Studies recommend using nonneutralizing antibodies against IFNγRα (different clones, such as PE Mouse AntiHuman CD119, Cat. No. 558937) for detection in scenarios where GIR208's neutralizing function may mask epitope recognition.

Typical experimental contexts for combining these reagents:

• Flow cytometry and immunofluorescence to detect IFNγRα (CD119) expression, using isotype controls and sometimes fluorophoreconjugated secondary antibodies as well.
• Functional blocking assays, often combining GIR208 with other IFNγ pathway blockers or agonists.
• Western blotting and ELISA, sometimes utilizing a combination of GIR208, nonneutralizing antiCD119 antibodies, or detection antibodies for IFNγ itself.

In summary, GIR301, isotype controls (like MOPC21), and recombinant IFNγ protein are the most commonly used reagents alongside GIR208 in published literature surrounding IFNγ receptor studies.

Key findings from scientific literature citing clone GIR208 focus on its use as a research tool targeting the human interferongamma receptor 1 (IFNγR1 or CD119), primarily as an isotype control to ensure experimental specificity and validity.

Essential findings include:

• Clone GIR208 is widely used as an isotype control antibody in both in vitro and in vivo experiments to rule out nonspecific or offtarget effects when studying interferon signaling, especially in mouse models where GIR208 itself does not block murine interferon signaling.
• GIR208 specifically recognizes human IFNγRα (CD119), which is a key component of the IFNγ receptor complex involved in JAKSTAT signaling. This makes it suitable for flow cytometry, functional assays, and as a control in experiments manipulating interferon pathways.
• It is reported for use in flow cytometric analysis and functional assays to confirm antibody specificity in experimental immunology.
• The antibody does not bind when IFNγ is already engaged to its receptor, and expression of the receptor is generally ubiquitous but low, with higher expression on certain immune cell subsets, such as monocytes.

Experimental context and supporting detail:

• GIR208 has been specifically cited as an isotype control in studies using antimouse IFNAR1 (clone MAR15A3) to discern effects of Type I interferon blockade.
• It is highlighted in translational models, such as C57BL/6J mice challenged with viral pathogens, to demonstrate that observed effects are due to specific antibody blockade rather than nonspecific immunoglobulin effects.
• The antibody is recommended to be carefully titrated for each application, with commonly cited concentrations for flow cytometry (≤0.5 μg per 10^6 cells).

In summary:

• GIR208 is integral for experimental controls in interferon signaling research due to its specificity for human IFNγR1 and lack of blocking activity in murine systems, thereby allowing robust discrimination between specific and nonspecific antibody effects in immunological assays.
• No primary literature describes GIR208 as an antagonist or therapeutic; its scientific utility lies in experimental controls and assay validation.

If you require summarized findings from specific highimpact papers or application fields (e.g., cancer immunology, antiviral immunity), please specify for more targeted synthesis.

Dosing Regimens of Clone GIR208 in Mouse Models

Standard Approach Across Models

The dosing regimen for clone GIR208, an antihuman IFNγ receptor (CD119) monoclonal antibody used as an isotype control in many experiments, is notably consistent across various mouse models and experimental conditions. The established protocol is a single intraperitoneal (i.p.) injection of 2 mg per mouse, administered one day before the experimental intervention. This dose and route are widely referenced in the literature, with no evidence of substantial variation between different mouse strains, disease models, or experimental contexts.

Published Examples and Model Variability

Several published studies specifically use this dosing regimen in C57BL/6J mice, a common wildtype background in immunology research. For example, a study comparing immune responses in the context of viral infection treated C57BL/6J mice with a single 2 mg dose of GIR208, observing no significant adverse effects or deviation from the standard protocol. Another publication confirms the use of this isotype control at the same fixed dose, with no mention of strainspecific adjustments. Some studies have tested a lower dose (0.2 mg) in wildtype mice, but this appears to be an exception rather than a routine variation.

Absence of Dose Titration or MultiDose Regimens

Unlike therapeutic or depleting antibodies (e.g., antiPD1, antiCD4, antiCD8), where dosing frequency and amount may be titrated based on target, model, or desired effect, GIR208 is used almost exclusively as a singledose, fixedconcentration isotype control. There is no evidence of repeated dosing, dose escalation, or modelspecific dose adjustments for GIR208 in the available literature. The simplicity and consistency of this regimen reflect its role as a negative control rather than an experimental variable.

Summary Table

Conclusion

The dosing regimen for clone GIR208 in mouse models is highly consistent: a single 2 mg i.p. injection administered one day prior to experimental intervention, regardless of mouse strain or disease model. Significant variation across models has not been reported, and dose titration or multidose regimens are not part of standard practice for this isotype control.